AI drug designer Chai hits $3.8bn as European pharma signs on
San Francisco startup Chai Discovery has tripled its valuation to $3.8 billion after a $400 million funding round, signalling that major European drugmakers are now paying to deploy generative AI in the race to design new medicines.
Chai Discovery has raised $400 million in a Series C round that triples its valuation to $3.8 billion in just seven months. The San Francisco startup has now accumulated over $600 million in total funding since its founding in 2024. The round was led by Index Ventures, with participation from Kleiner Perkins, Sequoia Capital, OpenAI, Thrive Capital, and Baillie Gifford.
Rather than screening existing molecule libraries, Chai uses generative AI to design new antibodies and proteins from scratch for specific diseases. Its Chai-2 model achieved double-digit success rates in lab testing, which the company claims is a hundredfold improvement over older methods. This technology has already moved beyond theoretical research into active commercial deployment.
Swiss drugmaker Novartis and immunology firm argenx are now using Chai's systems, alongside US-based Eli Lilly and Pfizer. For European pharmaceutical companies, adopting these tools represents a fundamental shift in research and development strategy. Large drugmakers rarely pay for unproven software, making these contracts a strong validation that AI-driven design is actively replacing traditional discovery methods.
Chai's rapid valuation growth reflects a massive capital surge into the AI biology sector. Competitors like Isomorphic Labs, a Google DeepMind spinout, raised $2.1 billion in May and also partnered with Novartis. Analysts estimate the AI drug-discovery market will grow from $2.35 billion this year to $13.7 billion by 2033, but investor appetite is currently moving much faster than those forecasts.
The true economic test for these inflated valuations lies ahead. While AI models can generate candidate molecules in minutes, those compounds still face years of laboratory work, clinical trials, and regulatory review before reaching patients. Chai and its rivals are betting that the next generation of medicines will be designed rather than discovered, but a $3.8 billion price tag ultimately depends on surviving the industry's inevitable clinical failures.
